

**Supplemental Table 1** Days until next cancer treatment for patients who contacted the patient navigator

Cancer Diagnosis (n=397 <sup>a</sup> )	Initiated Fertility Preservation	Did Not Undergo Fertility Preservation	<i>P</i> value
Breast Cancer	n=89	n=128	<i>NS</i>
Median	37	21	
(Range)	(16-95)	(0-93)	
Hematologic Cancers (lymphoma, leukemia)	n=31	n=50	0.021
Median	28	13	
(Range)	(18-57)	(0-98)	
Gynecologic Cancers (cervical, ovarian, uterine, endometrial)	n=16	n=26	<i>NS</i>
Median	43	20	
(Range)	(21-64)	(1-77)	
Other Cancers	n=20	n=37	<i>NS</i>
Median	31	15	
(Range)	(16-91)	(0-98)	
All Cancers	n=156 <sup>b</sup>	n=241 <sup>c</sup>	<0.001
Median	33	19	

(Range)	(16-95)	(0-98)	
---------	---------	--------	--

Significance did not change when including patients that required more than 100 days until next cancer treatment. Of note, 3 patients had 2 cycles prior to next treatment.

<sup>a</sup> n=65 did not have exact next cancer treatment date available in our records.

<sup>b</sup> n=16 >100d until next treatment, thus not included for analysis.

<sup>c</sup> n=19 >100d until next treatment, thus not included for analysis.

**Supplemental Table 2** COH cycle characteristics of patients not on oral contraceptive pills who underwent a cycle specific vs. random start protocol and completed an oocyte retrieval

Stimulation Measures (n=52 <sup>a</sup> )	Cycle Specific (n=30)	Random Start (n=22)	<i>P</i> value
Age			
Median	34	30	<i>NS</i>
(Range)	(20-41)	(19-39)	
BMI			
Median	22.62	24.60	<i>NS</i>
(Range)	(17.95-34.11)	(16.20-34.40)	
AMH (ng/ml)			
Median	1.50	4.33	<i>NS</i>
(Range)	(0-9.10)	(0-10.39)	
Peak E <sub>2</sub> (pg/ml)			
Median	1313	1432	<i>NS</i>
(Range)	(109-3439)	(55-4341)	
Number of days of stimulation			
Median	10	10	<i>NS</i>
(Range)	(7-13)	(7-15)	
Total FSH Dosage			

Median (Range)	1875 (750-6000)	1525 (750-5400)	<i>NS</i>
Total HMG Dosage			
Median (Range)	787 (375-1350)	750 (600-1800)	<i>NS</i>
Total number of oocytes retrieved			
Median (Range)	7 (2-55)	13 (1-30)	<i>NS</i>
Number of mature oocytes retrieved			
Median (Range)	6 (0-40)	10 (1-21)	<i>NS</i>
Number of oocytes cryopreserved			
Median (Range)	12 (0-22)	12 (0-25)	<i>NS</i>
Number of embryos cryopreserved			
Median (Range)	4 (0-12)	6 (0-16)	<i>NS</i>

Days to next cancer treatment <sup>a</sup>	n=24	n=18	
Median	40	34	NS
(Range)	(18-71)	(16-85)	

*AMH*, anti-Müllerian hormone; *BMI*, body mass index; *COH*, controlled ovarian

hyperstimulation; *E<sub>2</sub>*, estradiol; *HMG*, human menopausal gonadotropin; *PN*, patient navigator.

<sup>a</sup> n=6 that did not have next treatment date available in our records; n=4 >100d thus not included for analysis.

**Supplemental Table 3** Pregnancy outcomes after receiving cancer treatment for fertility

preservation patients that returned to use frozen embryos or oocytes

Patient Number (n=21)	Age at cryo-preservation	Age at return for implantation	Embryo or oocyte used?	Gestational carrier used?	Outcome
1	28.0	30.2	Embryo	Yes	Live singleton birth
2	29.7	31.8	Embryo	No	Live twin births
3	29.8	31.6	Embryo	No	Live singleton birth
4	30.3	36.4	Embryo	No	Live singleton birth
5	30.8	33.7	Embryo	No	No pregnancy
6	31.3	35.6	Embryo	No	No pregnancy
7	31.4	32.6	Embryo	No	No pregnancy
8	31.7	33.2	Embryo	No	Live singleton birth
9	32.0	34.9	Embryo	No	Live twin births
10	33.1	35.2	Embryo	Yes	Live singleton birth
11	34.9	40.6	Embryo	No	No pregnancy
12	36.3	41.0	Embryo	No	No pregnancy
13	36.3	37.7	Embryo	Yes	Live singleton birth
14	37.1	38.2	Embryo	No	Live singleton birth
15	37.6	38.1	Embryo	#1: No #2: Yes	Two separate live singleton births
16	38.9	41.9	Embryo	No	Live singleton birth
17	40.1	41.1	Embryo	Yes	No pregnancy
18	41.3	43.1	Embryo	No	No pregnancy
19	42.5	43.1	Embryo	Yes	No pregnancy
20	25.6	31.6	Oocyte	Yes	No pregnancy
21	41.1	42.3	Oocyte	No	Live twin births